Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 28 August 2024 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) - formerly known as Sosei Group or Sosei Heptares - notes the announcement by its partner Neurocrine Biosciences Inc. ( "Neurocrine".
| Ticker |
Sentiment |
Impact |
|
SOLTF
|
Neutral
|
7 %
|
|
NBIX
|
Somewhat Bullish
|
23 %
|
